Short Interest in Aptose Biosciences Inc. (NASDAQ:APTO) Increases By 46.5%

Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) saw a significant growth in short interest in June. As of June 15th, there was short interest totalling 112,800 shares, a growth of 46.5% from the May 31st total of 77,000 shares. Approximately 0.8% of the company’s shares are short sold. Based on an average trading volume of 69,100 shares, the days-to-cover ratio is presently 1.6 days.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on APTO shares. HC Wainwright restated a “buy” rating and issued a $7.00 price target on shares of Aptose Biosciences in a report on Friday, June 14th. Piper Sandler reaffirmed an “overweight” rating and set a $5.00 price objective on shares of Aptose Biosciences in a research report on Wednesday, April 3rd. StockNews.com started coverage on Aptose Biosciences in a research report on Saturday, June 22nd. They set a “hold” rating for the company. Finally, Canaccord Genuity Group reduced their price objective on Aptose Biosciences from $15.00 to $6.00 and set a “buy” rating for the company in a research report on Thursday, May 16th. One analyst has rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $14.83.

Institutional Trading of Aptose Biosciences

An institutional investor recently raised its position in Aptose Biosciences stock. Annandale Capital LLC grew its holdings in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 40.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 74,666 shares of the biotechnology company’s stock after buying an additional 21,334 shares during the period. Annandale Capital LLC owned 0.99% of Aptose Biosciences worth $209,000 at the end of the most recent quarter. 26.62% of the stock is currently owned by hedge funds and other institutional investors.

Aptose Biosciences Stock Performance

Shares of NASDAQ APTO opened at $0.76 on Friday. The stock has a 50 day moving average price of $1.05 and a 200 day moving average price of $1.61. Aptose Biosciences has a 52 week low of $0.71 and a 52 week high of $5.10. The stock has a market capitalization of $13.75 million, a PE ratio of -0.12 and a beta of 1.39.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last issued its quarterly earnings results on Tuesday, May 14th. The biotechnology company reported ($0.73) EPS for the quarter, beating the consensus estimate of ($0.82) by $0.09. As a group, research analysts forecast that Aptose Biosciences will post -2.67 EPS for the current year.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.